Paul Schloesser is a journalist covering the biopharmaceutical industry, currently writing for Endpoints News. With a focus on drug development, regulatory affairs, and biotech business strategies, Schloesser provides in-depth analysis of the latest trends and breakthroughs in the life sciences sector. His reporting highlights key industry deals, emerging technologies, and the challenges faced by pharmaceutical companies.